CRISPR-Cas9 gene editing technology has emerged as one of the most transformative advancements in medicine and biotechnology.

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Another company looking to initiate clinical trials with an epigenetic-editor-based treatment for hepatitis is nChroma Bio.

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic ...

The trial is structured to assess the safety and efficacy of the therapy in approximately 50 ATTRv-PN subjects.

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

While we drown breakthrough-science in red tape, China has a laser-like focus on speeding up scientific progress and adopting ...

The Cell Shuttle was designed to help academic cell therapy developers by providing an integrated, automated solution.

the first CRISPR-based therapy, in December 2023, the financial pressures continued amidst executive shifts, such as the departure of COO Julianne Bruno in March 2025. Finally, clinical trial ...

Previous skepticism turns to optimism as the first clinical trials for transplantation with genetically edited pig kidneys ...